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2ABSTRACT 
Monocarboxylate transporters (MCTs) are involved in lactate trafficking and utilization by 
brain cells. As lactate is not only overproduced during ischemia but its utilization was shown 
to be essential upon recovery, we analyzed the expression of the main cerebral MCTs at 1 and 
24 hours after an ischemic insult induced by a transient occlusion of the left middle cerebral 
artery (MCAO) in CD1 mice (n = 5, 7 and 10 for control, 1 and 24 hours groups, 
respectively). After 1 hour of reperfusion, an upregulation of the three MCTs was observed in 
the striatum (MCT1 ipsilateral 2.73 ± 0.2 and contralateral 2.01 ± 0.4; MCT2 ipsilateral 2.1 ± 
0.1; MCT4 ipsilateral 1.65 ± 0.1)  and in the surrounding cortex of both the ipsilateral (MCT1 
2.4 ± 0.4; MCT2 1.62 ± 0.2; MCT4 1.31 ± 0.1)  and contralateral (MCT1 2.78 ± 0.4; MCT2 
1.76 ± 0.2) hemispheres, compared to the corresponding sham hemispheres. An increase of 
MCT1 (ipsilateral 2.1 ± 0.2) and MCT2 (contralateral 1.9 ± 0.1) expression was also observed 
in the hippocampus, while no effect was observed for MCT4. At 24 hours of reperfusion, total 
MCT2 and MCT4 expressions were decreased in the striatum (MCT2 ipsilateral 0.32 ± 0.1 
and contralateral 0.63 ± 0.1; MCT4 ipsilateral 0.59 ± 0.1) and the surrounding cortex (MCT4 
ipsilateral 0.67 ± 0.1), compared to the sham. At the cellular level, neurons which usually 
express only MCT2 strongly expressed MCT1 at both time points. Surprisingly, staining for 
MCT4 appeared on neurons and was strong at 24 hours post-insult, in the striatum and the 
cortex of both hemispheres.  A similar expression pattern was observed also in the ipsilateral 
hemisphere of the sham operated animals at 24 hours. Overall, our study indicates that cell-
specific changes in MCT expression induced by an ischemic insult may participate to the 
metabolic adaptations taking place in the brain after a transient ischemic episode.  
Keywords: astrocyte; neuron; microvessel; monocarboxylate transporter; ischemia 
  
3
Stroke is the second leading cause of death worldwide  (World Health Organization 2014; 
http://www.who.int/mediacentre/factsheets/fs310/en) and the commonest cause of 
neurological disability in the developed world (Murray and Lopez 1996; MacDonald et al. 
2000). Ischemic stroke, resulting from an artery occlusion, is the most common subtype of 
stroke. In this case, oxygen and glucose supply from the blood is disrupted, leading to energy 
failure in the concerned area and causing damage to the brain tissue. Brain metabolism 
therefore plays a critical role in the pathophysiological mechanisms underlying neuronal 
damage in stroke and recovery. Glucose is the primary energy substrate of the brain under 
physiological conditions, but the brain is also able to oxidize other intermediate metabolites, 
notably lactate (Boumezbeur et al. 2010; Wyss et al. 2011). Lactate seems to occupy a central 
position under ischemic conditions. Indeed, during cerebral ischemia, lactate accumulates in 
the extracellular space due to the anaerobic metabolism of glucose. Levels can rise from 1.5–
3.5 mM in the normal brain to 15–25 mM in the ischemic brain (Rehncrona et al. 1981; 
Folbergrova et al. 1992; Wagner et al. 1992). Despite a long history of negatively perceived 
role in ischemia, lactate has been shown to have neuroprotective properties in hypoxic 
conditions in vitro (Schurr et al. 1997; Schurr et al. 1997; Berthet et al. 2009), but also in 
models of ischemia in vivo (Schurr et al. 2001; Berthet et al. 2009; Berthet et al. 2012). 
Indeed, Berthet et al. (2009, 2012) demonstrated that administration of lactate after 
reperfusion, either intracerebroventricularly or intravenously, decreased significantly the 
lesion size in mouse brain and improved the neurological outcome upon recovery from a 
transient middle cerebral artery occlusion (tMCAO).  
Lactate trafficking between cells is facilitated by a family of proton-dependent carriers named 
monocarboxylate transporters (MCTs). Three of them have been clearly characterized as 
lactate transporters in the central nervous system (Pierre and Pellerin 2005). MCT1 is 
predominantly found on endothelial cells forming cerebral blood vessels as well as on glial 
cells including astrocytes (Gerhart et al. 1997; Hanu et al. 2000; Pierre et al. 2000), 
oligodendrocytes (Lee et al. 2012; Rinholm et al. 2011) and tanycytes (Cortes-Campo et al. 
2011). MCT2 is considered the main neuronal transporter (Pierre et al. 2002; Debernardi et al. 
2003). Finally, MCT4 is exclusively expressed by astrocytes but its precise role is not well 
understood up to now (Rafiki et al. 2003; Pellerin et al. 2005; Rosafio and Pellerin 2014). 
Interestingly, Schurr et al. (2001) showed that inhibition of lactate transport through the 
MCTs increases neuronal damage after cardiac arrest-induced transient global cerebral 
ischemia in a rat model, thus suggesting a critical role for these transporters in the recovery 
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from ischemia. In this study, we investigated the changes in cerebral MCT expression pattern 
occurring in a MCAO ischemic mouse model. 
EXPERIMENTAL PROCEDURES 
All experiments were conducted in accordance with the Swiss guidelines for animal 
experimentation and approved by the veterinary authority. 
Transient middle cerebral artery occlusion in the mouse 
Male CD1 mice (body weight 26-35 g, 5-7 weeks of age; Charles River, L’arbresle, France) 
were anesthetized with isoflurane (1.5 - 2% in nitrous oxide/oxygen 70%/30%) using a face 
mask. Body temperature was maintained at 37.0 ± 0.5°C throughout surgery using a heating 
pad (FHC Inc., Bowdoinham, ME, USA). Regional cerebral blood flow (rCBF) was measured 
and continuously recorded throughout the operation in all animals by laser-Doppler flowmetry 
(Perimed, Craponne, France) with a flexible probe fixed on the skull (1 mm posterior and 6 
mm lateral from bregma). Transient (30 minutes) focal cerebral ischemia was induced by 
occlusion of the left MCA with an intra-arterial suture as described previously (Longa et al. 
1989; Berthet et al. 2009). Briefly, the left common carotid artery and the left external carotid 
artery were exposed and ligated following a ventral midline neck incision. Ischemia was 
induced by inserting a silicon-coated nylon monofilament (0.17 mm diameter) through the left 
common carotid artery into the internal carotid artery until mild resistance was felt and a drop 
to less than 20% of initial rCBF was registered. rCBF was monitored and maintained below 
20% of the baseline level during ischemia. Reperfusion was considered successful if the rCBF 
rose above 50% of baseline. Sham mice underwent exclusively the common carotid artery 
ligation during 30 minutes.  
At the beginning of the operation, mice were administered 0.025 mg/kg of buprenorphine 
subcutaneously for post-surgery analgesia. Once the animals were awake, they were housed 
overnight in an incubator at 28°C.  
Western blotting 
For protein expression experiments, young adult male mice were subjected to 30 minutes 
MCAO as described above and sacrificed either 1 hour or 24 hours after reperfusion. Striatum 
(caudate and putamen), primary motor and somatosensory cortex and hippocampus were 
collected using a rodent brain matrix (adult mouse, coronal. ASI Instruments, MI, USA). 
Total proteins were extracted from brain tissues by cellular lysis in ice-cold RIPA buffer 
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(#9806, Cell Signaling, Beverly, MA, USA) supplemented with a mixture of protease 
inhibitors (Complete 11257000; Roche, Basel, Switzerland). Protein quantification was 
performed with the Pierce BCA Protein Assay kit (#23227, Thermo Fisher Scientific, Pierce, 
Lausanne, Switzerland) and about 20 µg of proteins were denatured (95°C) during 5 minutes 
in SDS-PAGE sample buffer (60 mM Tris-HCl pH 6.8, 5 % SDS, 6.6 % glycerol, 5 mM 
EDTA, 5 % β-mercaptoethanol and 0.1 % bromophenol blue). Samples were separated on a 
10 % acrylamide running gel and a 4 % acrylamide stacking gel using an Electrophoresis Unit 
(Bio-Rad, Cressier, Switzerland). Proteins were then electroblotted onto nitrocellulose 
membranes (0.45 µm; #162-0115, Bio-Rad, Cressier, Switzerland) using an Electrophoresis 
Unit. Non-specific binding sites were blocked for 1 hour at room temperature with a solution 
of Tris-Buffered-Saline (TBS; 50 mM Tris-HCl pH 7.5, 150mM NaCl) supplemented with 
0.1 % Tween-20 and containing 10 % (wt/vol) of skimmed milk. Blots were then incubated 
overnight at 4°C with specific primary antibodies in TBS-T 0.1 % containing 1 % skimmed 
milk: polyclonal rabbit anti-mouse MCT1 (1:1000 dilution; (Pierre et al. 2000)), polyclonal 
rabbit anti-mouse MCT2 (1:1000 dilution; (Pierre et al. 2000)) or polyclonal rabbit anti-
mouse MCT4 (1:200 dilution; #sc-50329; SantaCruz, Heidelberg, Germany). Blots were 
washed three times in TBS-T 0.1% and subsequently incubated 2 hours at room temperature 
with horseradish peroxidase-conjugated donkey anti-rabbit IgG (#NA9340V, 1:10.000 
dilution; GE Healthcare, Glattbrugg, Switzerland). After being washed three times in TBS-T 
0.1%, blots were processed using Immun-StarTMWesternCTM Chemiluminescent Kit (#170-
5070, Bio-Rad, Cressier, Switzerland). Chemiluminescence detection was performed with the 
ChemiDoc™ XRS System (#170-8070, Bio-Rad, Cressier, Switzerland). Total protein content 
assay was performed with the Pierce Reversible Protein Stain kit (#24580, Thermo Fisher 
Scientific, Pierce, Lausanne, Switzerland) and revealed with the ChemiDoc™ XRS System 
(#170-8070, Bio-Rad, Cressier, Switzerland). Both types of labeling were quantified with the 
ImageLab 3.0 software (Bio-Rad, Cressier, Switzerland) and MCT protein expression was 
normalized to the total protein content. All data were normalized to the corresponding 
ipsilateral area of the sham. 
Immunohistochemistry 
Mice were injected intraperitoneally with a lethal dose of pentobarbital (10mL/kg, Sigma, 
Buchs, Switzerland) and then perfused with 150mL of 4% paraformaldehyde (Sigma-Aldrich, 
USA) dissolved in 1 x PBS at pH 7.4. Brains were dissected, postfixed overnight at 4°C, 
cryoprotected 24 hours in 30% sucrose solution (Sigma-Aldrich, USA) and rapidly frozen. 
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Twenty µm thick coronal microtome-cryostat (leica MC 3050S) sections were stored in 
cryoprotectant (30% ethylene glycol and 25% glycerin in 1 x PBS) at -20°C. For 
immunostaining, sections were washed three times in 1 x PBS and blocking of non-specific 
binding sites was achieved by incubating in 1 x PBS containing 0.25% bovine serum albumin, 
0.3% Triton X-100 and 10% normal goat serum during 1 hour. Double immunostainings were 
carried out overnight at 4°C in PBS containing 0.25% bovine serum albumin, 0.3% Triton X-
100: polyclonal anti-MCT1 and anti-MCT2 (1:500 dilution; (Pierre et al. 2000)), polyclonal 
anti-MCT4 (1:250 dilution; #sc-50329; SantaCruz, Heidelberg, Germany) in combination 
with either a monoclonal mouse anti-neuronal nuclear antigen (NeuN) antibody (1:500 
dilution, Sigma, Buchs, Switzerland), a monoclonal mouse anti-microtubule associated 
protein (MAP2) antibody (1:250 dilution, Sigma, Buchs, Switzerland) or a monoclonal anti-
S100β (1:500 dilution; Sigma, Buchs, Switzerland). After washing three times with PBS, 
sections were incubated in a PBS solution containing a donkey Cy3-conjugated anti-rabbit 
antibody (1:500 dilution; #711-165-152, Jackson Immunoresearch, Baltimore, MD, USA) and 
a donkey FITC-conjugated anti-mouse antibody (1:500 dilution; #715-095-150, Jackson 
Immunoresearch, Baltimore, MD, USA). After washing twice in PBS, sections were 
incubated during 5 minutes with Hoechst staining solution (#94403, Sigma, Buchs, 
Switzerland) dissolved in PBS (1/10’000), rinsed again twice 10 minutes in PBS and then 
mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). 
Preparations were then maintained at 4°C until observation with a Zeiss LSM 710 Quasar 
Confocal Microscope (Zeiss, Feldbach, Switzerland). 
Statistical analysis 
Statistical analyses were performed using either a one-way ANOVA followed by Dunnett’s 
multiple comparison test or a Student t-test. Statistical calculations were carried out using 
GraphPad-Prism 6.0 (GraphPad Software, San Diego, CA, USA). Data are presented as mean 
± s.e.m. P < 0.05 was considered statistically significant. 
RESULTS 
Quantitative changes of MCT expression in striatum, cortex and hippocampus at 1 hour 
and 24 hours post-ischemia 
The protein expression levels of MCT1, MCT2 and MCT4 were evaluated by Western 
blot in three distinct brain areas both from the ipsilateral and contralateral hemisphere at an 
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early (1 hour) and a later (24 hours) time point following ischemia and reperfusion. At 1 hour 
post-ischemia, MCT1 expression was increased in the ischemic mouse brain in all structures 
analyzed (Figure 1A). Thus, a significant increase was reported both in the ipsilateral (2.73 ± 
0.2) and contralateral striatum (2.01 ± 0.4) when compared to sham. Similarly, enhanced 
levels were observed also in the ipsilateral (2.41 ± 0.4) and contralateral (2.78 ± 0.4) cortex. 
Interestingly, an increase in MCT1 expression was also observed in more remote regions like 
the hippocampus, reaching significance for the ipsilateral hemisphere (2.1 ± 0.2). In contrast, 
significant differences in MCT1 expression were no longer observed at 24 hours in any region 
examined (Figure 1B). At 1 hour post-ischemia, MCT2 expression was increased in the 
striatum (2.1 ± 0.1) and the cortex (1.62 ± 0.2) of the ischemic hemisphere compared to the 
sham. In addition, a significant increase was observed in the cortex (1.76 ± 0.2) and in the 
hippocampus (1.9 ± 0.1) of the contralateral hemisphere (Figure 1C). On the contrary, at 24 
hours post-ischemia, MCT2 expression was reduced in all structures analyzed in both the ipsi- 
and contralateral hemisphere, reaching significance in the striatum, both in the ipsilateral 
(0.32 ± 0.1) and contralateral (0.63 ± 0.1) hemispheres, and in the ipsilateral hippocampus 
(0.63 ± 0.1) (Figure 1D). Finally, MCT4 expression was increased in the ipsilateral 
hemisphere for both the striatum (1.65 ± 0.1) and the cortex (1.31 ± 0.1) at 1 hour post-
ischemia (Figure 1E). In contrast, at 24 hours post-ischemia, the opposite effect was observed 
for MCT4 expression with a decrease in the ischemic striatum and cortex in comparison to 
sham (respectively 0.59 ± 0.1 and 0.67 ± 0.1) (Figure 1F).  
Cellular changes in MCT expression at 1 hour and 24 hours post-ischemia. 
In order to obtain more information about the cellular elements which might exhibit 
changes in MCT expression, an immunofluorescence characterization was performed. Under 
basal conditions, MCT1 immunoreactivity had been observed essentially in the neuropil as 
well as on endothelial cells of capillaries as described previously (Pierre et al. 2000). Here we 
report the appearance of a strong MCT1 staining on neuronal cell bodies in the striatum 
(Figure 2B-C), and an even more intense staining in the cortex (Figure 2E-F) of ischemic 
animals at 1 hour post-ischemia, as compared to the sham hemispheres (Figure 2A and 2D). 
Blood vessels appear to be more intensely labelled as well in ischemic animals compared to 
the sham in both structures. Moreover, the overall neuropil staining was clearly enhanced in 
both areas for both hemispheres. This observation most likely explains the significant increase 
of MCT1 expression detected by Western blot (Figure 1A). At 24 hours post-ischemia in the 
striatum, the intensity of the neuropil labelling and the number of neurons labelled decreased 
8compared to 1 hour post-ischemia (Figure 2H-I). In the cortex, MCT1 expression in the 
neuropil was reduced compared to 1 hour post-ischemia, especially in the ischemic 
hemisphere (Figure 2K-L). Interestingly, at 24 hours after surgery, neuronal cell bodies 
became positive for MCT1 in the sham hemispheres, in the striatum (Figure 2G) and even 
more in the cortex (Figure 2J) with a small enhancement of the neuropil labelling. Such an 
induction in the sham might explain the absence of difference observed between the sham and 
the ischemic animals by western blotting 24 hours post-ischemia (Figure 1B). This 
observation reveals an effect of the sham condition per se (a transient reduction in blood flow 
due to 30 min CCA ligation) on brain metabolism.  
Under basal conditions, MCT2 expression was reported to be abundantly expressed in 
the neuropil associated with neuronal elements, mainly on processes and spines (Pierre et al. 
2002; Bergersen et al. 2005). At 1 hour post-ischemia, while most neuronal cell bodies were 
barely stained for MCT2 in the sham (Figure 3A and 3D), in the ischemic animals neuronal 
cell bodies were intensely stained in the striatum and even more in the cortex of both 
hemispheres (Figure 3B-C and 3E-F, respectively). Moreover, the neuropil staining was also 
more intense. Interestingly, endothelial cells forming blood vessels exhibited a slight MCT2 
expression in ischemic animals (Figure 3B-C and 3E-F), which was not present in brain areas 
from sham animals (Figure 3A and 3D). These data are consistent with the quantitative 
measurements obtained by Western blot (Figure 1C). At 24 hours post-ischemia, a strong 
reduction of the overall MCT2 expression was observed in the ipsilateral hemispheres of 
ischemic animals (Figure 3I and 3L) in accordance with the Western blot data (Figure 1D). In 
parallel, MCT2 expression associated with blood vessels was strongly increased in all cases 
(Figure 3G-L), including in brain areas from sham animals (Figure 3G and 3J). MCT2 
expression on microvessel elements was previously reported but was scarce under non-
ischemic conditions (Pierre et al. 2000).  
MCT4 is normally expressed exclusively on astrocytes (Rafiki et al. 2003). Here we 
confirmed that MCT4 colocalizes with the astrocytic marker S100β in both brain areas of the 
sham (Figure 4A and 4D). At 1 hour post-ischemia, the overall MCT4 staining was strongly 
enhanced in the striatum and cortex of both ipsilateral and contralateral hemispheres (Figure 
4B-C and 4E-F) compared to the sham. It was also noticed that some cells which are negative 
for the S100β staining exhibit MCT4 labelling. A few of them were found in brain areas from 
sham animals (Figure 4A and 4D), and much more in both the striatum (Figure 4C) and the 
cortex (Figure 4F) of ischemic hemispheres. At 24 hours, similarly to MCT1 expression, 
some cells resembling neurons were clearly stained for MCT4 in the striatum of the ischemic 
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hemisphere (Figure 4I), and in the cortex of both hemispheres, even though the labeling was 
less intense in the ipsilateral hemisphere (Figure 4K-L). Interestingly, both structures in the 
sham presented also neuronal-like cell associated MCT4 staining (Figure 4G and 4J), 
highlighting the likely effect of the sham treatment on brain metabolism. In order to confirm 
the presence of MCT4 on neurons, double labeling experiments with the neuronal marker 
NeuN were performed. Indeed, many cells stained for the neuronal marker NeuN in the 
striatum at 1 hour (Figure 5A-C) and 24 hours (Figure 5G-I) post-ischemia as well as in the 
cortex at 1 hour (Figure 5D-E) and 24 hours (Figure 5J-L) post-ischemia exhibited MCT4 
staining. Results obtained by immunofluorescence suggest that the increased MCT4 
expression observed by western blot at 1 hour compared to the sham (Figure 1E) might be 
attributable to enhanced astrocytic expression, while at 24 hours the lack of difference 
observed in western blot might be due to the increase in neuronal MCT4 expression in the 
sham (Figure 1F).  
Energetic shortage caused by interruption of oxygen and glucose supply during ischemic 
stroke leads to metabolic adaptations promoting a switch between oxidative and glycolytic 
metabolism (Arnberg et al. 2015). Such phenotypic changes lead first to the production and 
the accumulation in the extracellular space of large amounts of lactate (Bruhn et al. 1989; 
Jones et al. 2000; Thoren et al. 2006). In this context, lactate transport through 
monocarboxylate transporters might play an important role in the new metabolic processes 
that take place during and following ischemia. Indeed, it has been shown that inhibition of 
lactate transport by acting on MCTs increases neuronal damage in different rat models of 
cerebral ischemia (Schurr et al. 2001; Wang et al. 2011). Thus, an analysis of cerebral MCT 
expression pattern following ischemia is essential to understand the metabolic reprogramming 
occurring in the brain upon reperfusion, and also to explain the reported protective role of 
lactate under such a condition (Berthet et al. 2009; 2012). So far, only few studies have 
investigated the cell-specific changes in the expression of MCTs occurring in different rat 
models of ischemia (Tseng et al. 2003; Zhang et al. 2005; Moreira et al. 2009; Geng et al. 
2015). However, none of those studies thoroughly examined the cell-specific evolution in the 
expression of the three MCT isoforms at the protein level after ischemia. In our study, not 
only global changes of expression for all three MCT isoforms were observed, but the cell-
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specific pattern of expression was found to be modified following ischemia. The cell-specific 
changes observed have been summarized in a schematic form in Figure 6. 
Modification of neuronal MCT expression following transient MCAO and reperfusion 
Under normal conditions, neurons strongly express the high affinity transporter MCT2 
(Figure 6A; Pierre et al. 2000; Pierre et al. 2002). Pharmacological inhibition of MCT2 was 
found to be deleterious in neuronal cultures exposed to OGD (An et al. 2014), but also in 
MCAO in rat, while MCT2 overexpression led to a reduced infarct size (Wang et al. 2011). 
Although the authors showed the importance of MCT2 activity for protection from ischemia, 
they did not assess in that study the impact of MCAO itself on MCT2 expression. Our data 
show that MCT2 expression is increased at 1 hour post-ischemia in neurons of all brain areas 
analyzed, in the ipsilateral and contralateral hemispheres. Such an early enhancement in 
MCT2 expression on neurons is consistent with the fact that MCT2 expression is regulated 
primarily at the translational level in neurons, allowing for a rapid protein synthesis following 
stimulation (Chenal and Pellerin 2007; Chenal et al. 2009; Robinet and Pellerin 2010). This 
response might offer a first mechanism to preserve neurons from the consequences of an 
ischemic insult such as excitotoxicity (Lai et al. 2014). Indeed, it was shown that 
overexpression of MCT2 in neurons together with lactate availability protects them from an 
excitotoxic insult in vitro (Bliss et al. 2004). Interestingly, in addition to enhanced MCT2 
expression, appearance of MCT1 on neurons was observed at this time point (Figure 6B). 
Neuronal MCT1 immunoreactivity is not detected under normal physiological conditions in 
the mouse brain (Pierre et al. 2000; Pierre et al. 2002), except in some rare neuronal 
populations (Lee et al. 2012). However following ischemia, neuronal MCT1 expression was 
reported in the rat hippocampus (Tseng et al. 2003) and in the hypertensive rat cortex (Zhang 
et al. 2005). If we consider that postischemic glucose utilization is depressed between 1 and 
48 hours in the neocortex and the striatum (Pulsinelli et al. 1982; Thoren et al. 2006), and that 
despite this fact, the ATP/ADP ratio and phosphocreatine content are essentially preserved 
during reperfusion (Thoren et al. 2006), it seems likely that neurons modify their metabolism 
by increasing MCT2 expression and by inducing MCT1 expression in order to favor lactate 
utilization while sparing glucose during reperfusion, at least in the first hours post-ischemia. 
Since glucose utilization is depressed, the increase in MCT1 and MCT2 expression observed 
in our study is unlikely to be related to a hypothetical increased glycolysis, but rather that the 
most likely purpose of their induction would be to allow neuronal lactate uptake and oxidation 
with reperfusion rather than release. Since the affinity of MCT1 for lactate is lower than 
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MCT2, it would make it ideal for the transport of lactate inside neurons when extracellular 
lactate concentrations are elevated like following ischemia. Moreover, several studies are 
supporting this idea. In fact, in vitro experiments showed that ischemic neurons enhance their 
ability to utilize lactate as an energy substrate and that lactate, but not glucose, is necessary 
for the recovery of synaptic function from hypoxia (Schurr et al. 1997a; Schurr et al. 1997b; 
Kitano et al. 2002). Thus, both increased MCT1 and MCT2 expression observed at 1 hour 
post-ischemia may reflect a first metabolic reprogramming to the post-ischemic environment 
(i.e. with reperfusion), in which neurons might oxidize more lactate to sustain their energy 
needs instead of glucose.  
At 24 hours post-ischemia, while neurons were still strongly expressing MCT1, we observed a 
general decrease in MCT2 expression, in both the ipsilateral and contralateral hemispheres, as 
highlighted by the difference in band intensities at 24 hours compared to 1 hour post-
ischemia. Such a phenomenon was also recently observed in another model of hypoxic 
ischemia in young mice (Zovein et al. 2004). Although neuronal cell death might contribute to 
this reduced expression in the ischemic hemisphere, it would not explain the decrease in the 
contralateral hemisphere, thus arguing for a specific decrease in expression (Figure 6C). 
Interestingly, at this later time point, MCT4 expression was observed on the somata of dying 
neurons in the lesion (striatum), but also on healthy neurons of the surrounding and more 
distant structures (cortex and hippocampus). While only a few of them were expressing 
MCT4 at 1 hour post-ischemia, at 24 hours post-ischemia most of them displayed such 
expression (Figure 6C). Up to now, MCT4 was considered as an exclusive astrocytic 
transporter under physiological conditions (Bergersen et al. 2002; Rafiki et al. 2003; Pellerin 
et al. 2005). But similarly to MCT1 expression, appearance of MCT4 on neurons was reported 
previously in the context of obesity, in ob/ob mice and in high fat diet-induced obese mice, as 
well as in db/db diabetic mice (Pierre et al. 2007). It seems likely that MCT1, and later on 
MCT4, might play an important role for neurons to achieve a new metabolic state following 
ischemia. Since MCT4 expression was shown to be under the control of the transcriptional 
factor HIF-1α (Ullah et al. 2006), it can be suggested that neuronal MCT4 expression could 
be part of a neuroprotective mechanism activated by HIF-1α, as previously demonstrated 
through a pharmacological stabilization of HIF-1α in both rat and mouse ischemic stroke 
models, for which the authors showed a reduction in the infarct volume and improved 
behavior (Nagel et al. 2011; Reischl et al. 2014). Strenghtening this point, loss of HIF-1α 
function in neurons was shown to increase their susceptibility to hypoxia-induced death both 
  
12
in vitro and in vivo (Baranova et al. 2007; Vangeison et al. 2008). Of note, an induction of 
MCT1 and MCT4 expression in neurons was observed also in the sham hemisphere at 24 
hours post-ischemia. If we consider that due to the common carotid ligation, cerebral blood 
flow (CBF) is reduced in the sham condition between 80 to 50% of the initial measurement 
and that in our experimental model we consider true ischemia when it drops below 20%, it 
can be suggested that a moderate and rather short duration reduction in oxygen and metabolite 
supply is sufficient to influence some metabolic characteristics of neurons.  
The particular pattern of MCT isoform expression in neurons reported here seems to reflect a 
complicated metabolic reprogramming that should allow them to face the metabolic 
challenges imposed on them following ischemia. However, such important processes need to 
be further investigated. Indeed, it is unknown if MCT1, and especially later on, MCT4 
expression, contribute to enhanced lactate uptake and utilization by these cells, or rather if it 
would be associated with an hyperglycolytic neuronal metabolism at this stage of reperfusion 
after MCAO. Indeed, oxidative metabolism was generally decreased following stroke (Sims 
and Muyderman 2010) and in humans, glucose metabolism was found to be increased in the 
contralateral hemisphere (Mountz et al. 2003). Thus, it could be that a certain proportion of 
neurons progressively switch to a hyperglycolytic metabolism when glucose supply is 
restored, which could explain the large accumulation of lactate observed up to several days 
following cerebral ischemia (Rehncrona et al. 1981; Folbergrova et al. 1992; Wagner et al. 
1992) 
Modification of astrocytic MCT expression following transient MCAO and reperfusion  
Under normal conditions, astrocytes express MCT1 (Gerhart et al. 1997; Hanu et al. 2000; 
Pierre et al. 2000) and MCT4 (Rafiki et al. 2003; Pierre and Pellerin 2005; Rosafio and 
Pellerin 2014) (Figure 6A). Recently, it was demonstrated that oxygen levels regulate MCT4 
expression in primary cultures of mouse cortical astrocytes (Rosafio and Pellerin 2014). Our 
observation that MCT4 expression on astrocytes in the ipsilateral hemisphere increased at 1 
hour post-ischemia and then comes back to pre-ischemic levels at 24 hours post-ischemia 
would be consistent with an oxygen-dependent regulation of MCT4 transcription. Indeed, at 
this later time point, re-oxygenation would display its effect and might downregulate MCT4 
expression in astrocytes by inhibiting the HIF-1α-dependent pathway. It is of interest to note 
that the neuroprotective effect produced by pharmacological stabilization of HIF-1α observed 
in ischemic stroke models of both rat and mouse (Nagel et al. 2011; Reischl et al. 2014) could 
be related also to the initial induction of astrocytic MCT4 expression. Thus, metabolic 
  
13
reprogramming in astrocytes is essentially taking place in the first hours following ischemia, 
and might contribute to protect neurons by allowing prominent lactate release that can be used 
by neurons as an alternative energy fuel upon reperfusion. 
Modification of microvessel-associated MCT expression following transient MCAO and 
reperfusion 
As a key element of the “tripartite synapse” (Perez-Alvarez and Araque 2013), microvessels 
play also an important role in brain metabolism. Due to the blood-brain barrier disruption 
occurring with stroke, cerebral blood vessels are strongly affected in such a condition 
(Moskowitz et al. 2010). In a paradigm of ischemia and reperfusion, it seems reasonable to 
assume that the metabolism of cells composing the microvasculature will be altered as well. 
In this study, it was found that microvessels undergo a strong enhancement of their MCT1 
expression in mice at 1 hour and at 24 hours post-ischemia. A similar observation was 
previously reported in a rat model of global ischemia (Zhang et al. 2005). In addition, at 24 
hours post-ischemia, a strong MCT2 expression appeared on microvessels, an observation that 
was never reported in ischemia up to now, although such a peculiar expression was previously 
reported on several microvessel-associated elements under physiological conditions (Pierre et 
al. 2000). The specific cellular localization of MCT2 expression associated with microvessels 
will need to be further confirmed in order to eventually understand its precise role. 
Nevertheless, in view of these observations, it can be concluded that microvessel-associated 
elements seem to participate also to the metabolic reprogramming taking place in response to 
ischemia. 
Metabolic reprogramming on the contralateral side of the lesion 
It is inferred that modifications in MCT expression occurring after an ischemic event are part 
of a large metabolic reprogramming that affect not only all cell types within the lesion, but 
also around it and in more remote regions. Indeed, modified MCT expression was also 
observed in the contralateral hemisphere, suggesting a metabolic reprogramming even in the 
unlesioned side of the brain. Previously, effects on MCT expression in the contralateral side 
were observed in a model of traumatic brain injury (Moreira et al. 2009), while increased 
glucose metabolism was observed in the contralateral cortical area after stroke in humans 
(Mountz et al. 2003). Moreover, we observed that expression of MCTs was modified also in 
more remote structures such as the hippocampus. Effects on remote areas caused by a focal 
lesion have been well documented in several ischemia models and can affect both mRNA and 
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protein expression (Witte et al. 2000). Other factors such as spreading depression and motor 
compensation during the recovery period might also contribute to the remote alterations 
observed both in the ipsilateral and contralateral hemispheres.  
CONCLUSIONS 
Significant changes in the expression of MCTs take place in the ischemic brain at different 
time points of recovery following the ischemic event (see Figure 6 for the overview), 
supporting the concept of metabolic reprogramming occurring in various cell types. In 
particular, the unexpected neuronal expression of the MCT1 and MCT4 isoforms, and the 
expression of MCT2 on the microvasculature will deserve to be further investigated to 
understand their exact role. Notwithstanding, these events appear to concur to promote 
recovery from the ischemic insult and favor adaptation to a new environment. Thus, efforts to 
promote the expression and efficiency of monocarboxylate transporters might well represent a 
new therapeutic avenue to try to reduce the adverse outcomes of stroke in patients. 
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FIGURE LEGENDS 
Figure 1. Quantitative immunoblot analysis of MCT1, MCT2 and MCT4 expression in the 
ipsi- and contralateral striatum, cortex, and hippocampus following 30 minutes MCAO and 
reperfusion in mice.  (A) MCT1 expression at 1 hour of reperfusion following MCAO in both 
the ipsilateral and contralateral hemisphere vs. sham. (B) MCT1 expression at 24 hours of 
reperfusion following MCAO in both the ipsilateral and contralateral hemisphere vs. sham. 
(C) MCT2 expression at 1 hour of reperfusion following MCAO in both the ipsilateral and 
contralateral hemisphere vs. sham. (D) MCT2 expression at 24 hours of reperfusion following 
MCAO in both the ipsilateral and contralateral hemisphere vs. sham. (E) MCT4 expression at 
1 hour of reperfusion following MCAO in both the ipsilateral and contralateral hemisphere vs. 
sham. (F) MCT4 expression at 24 hours of reperfusion following MCAO in both the 
ipsilateral and contralateral hemisphere vs. sham. Values of MCT expression were normalized 
to the total protein content. An ANOVA followed by Dunnett’s multiple comparison test was 
performed for statistical analysis. (*P <0.05, **P < 0.01 and ***P < 0.001). For sham n = 3; 
For MCAO  at 1 hour n = 5; For MCAO at 24 hours n = 7. 
Figure 2. Immunocytochemical analysis of MCT1 expression in the ipsi- and contralateral 
striatum and cortex following 30 minutes MCAO and reperfusion in mice. (A-C) MCT1 
expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral and 
contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker NeuN (in green). (D-F) MCT1 
expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral and 
contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker NeuN (in green). (G-I) MCT1 
expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral and 
contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker NeuN (in green). (J-L) MCT1 
expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral and 
contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker NeuN (in green). Nuclei are 
labeled with DAPI (in blue). White arrows on image and in inset indicate examples of 
colocalization between MCT1 (in red) and the neuronal marker NeuN (in green) present in 
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neuronal nuclei. White arrowheads (>) indicate blood vessels expressing MCT1 (in red). 
Scale bar = 40 µM. For sham n = 2; For MCAO  at 1 hour n = 2; For MCAO at 24 hours n = 
3. For each animal, 5-10 sections were examined for each structure.
Figure 3. Immunocytochemical analysis of MCT2 expression in the ipsi- and contralateral 
striatum and cortex following 30 minutes MCAO and reperfusion in mice. (A-C) MCT2 
expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral and 
contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker MAP2 (in green). (D-F) MCT2 
expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral and 
contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker MAP2 (in green). (G-I) MCT2 
expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral and 
contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker MAP2 (in green). (J-L) MCT2 
expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral and 
contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. Inset, Double 
immunolabeling on the same section with the neuronal marker MAP2 (in green). Nuclei are 
labeled with DAPI (in blue). White arrows on image and in inset indicate examples of 
colocalization between the neuronal marker MAP2 (in green) and MCT2 (in red). White 
arrowheads (>) on image or inset indicate blood vessels, in some cases expressing MCT2 (in 
red). Scale bar = 40 µM. For sham n = 2; For MCAO  at 1 hour n = 2; For MCAO at 24 hours 
n = 3. For each animal, 5-10 sections were examined for each structure. 
Figure 4. Immunocytochemical analysis of astrocytic MCT4 expression in the ipsi- and 
contralateral striatum and cortex following 30 minutes MCAO and reperfusion in mice. (A-C) 
MCT4 expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral 
and contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, 
Double immunolabeling on the same section with the astrocytic marker S100β (in green). (D-
F) MCT4 expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral 
and contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, 
Double immunolabeling on the same section with the astrocytic marker S100β (in green). (G-
I) MCT4 expression (in red) in the striatum of sham animals and in the striatum of the 
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ipsilateral and contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. 
Inset, Double immunolabeling on the same section with the astrocytic marker S100β (in 
green). (J-L) MCT4 expression (in red) in the cortex of sham animals and in the cortex of the 
ipsilateral and contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. 
Inset, Double immunolabeling on the same section with the astrocytic marker S100β (in 
green). Nuclei are labeled with DAPI (in blue). White arrows on image and in inset indicate 
examples of colocalization between the astrocytic marker S100β(in green) and MCT4 (in 
red). For sham n = 2; For MCAO  at 1 hour n = 2; For MCAO at 24 hours n = 3. For each 
animal, 5-10 sections were examined for each structure. 
Figure 5. Immunocytochemical analysis of neuronal MCT4 expression in the ipsi- and 
contralateral striatum and cortex following 30 minutes MCAO and reperfusion in mice. (A-C) 
MCT4 expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral 
and contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, 
Double immunolabeling on the same section with the neuronal marker NeuN (in green). (D-F) 
MCT4 expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral 
and contralateral hemispheres of mice at 1 hour of reperfusion following MCAO. Inset, 
Double immunolabeling on the same section with the neuronal marker NeuN (in green). (G-I) 
MCT4 expression (in red) in the striatum of sham animals and in the striatum of the ipsilateral 
and contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. Inset, 
Double immunolabeling on the same section with the neuronal marker NeuN (in green). (J-L) 
MCT4 expression (in red) in the cortex of sham animals and in the cortex of the ipsilateral 
and contralateral hemispheres of mice at 24 hours of reperfusion following MCAO. Inset, 
Double immunolabeling on the same section with the neuronal marker NeuN (in green). 
Nuclei are labeled with DAPI (in blue). White full arrows on image and in inset indicate 
examples of colocalization between MCT4 (in red) and the neuronal marker NeuN (in green) 
present in neuronal nuclei. White empty arrows indicate NeuN positive neurons (in green) 
which do not express MCT4 on their cell body. Scale bar = 40 µM. For sham n = 2; For 
MCAO  at 1 hour n = 2; For MCAO at 24 hours n = 3. For each animal, 5-10 sections were 
examined for each structure. 
Figure 6. Schematic representations of the major cell-specific changes in MCT expression 
following ischemia and reperfusion in mice. (A) Under normal conditions, neurons essentially 
24
express MCT2, astrocytes exhibit both MCT1 and MCT4 expression while endothelial cells 
forming blood vessels display MCT1 expression. (B) At 1 hour of reperfusion following the 
ischemic episode, a strong enhancement of MCT1 expression by blood vessels and of MCT4 
expression by astrocytes is observed. In parallel, neurons not only display enhanced MCT2 
expression, but they also start to exhibit MCT1 expression. (C) At 24 hours of reperfusion 
following  the ischemic episode, MCT4 expression on astrocytes returns to basal levels. On 
blood vessels, MCT1 expression remains elevated but MCT2 expression become visible. 
Finally, while MCT1 and MCT4 expression on neurons is still enhanced, neuronal MCT2 
expression decreases below basal levels. 
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Highlights 
• After 1 hour, MCT1, MCT2 and MCT4 expressions were upregulated in the ipsilateral
and contralateral striatum and cortex
• Neuronal MCT2 but also MCT1 expression, astrocytic MCT4 expression and
microvessel MCT1 expression all increased at 1 hour
• After 24 hours, overall MCT2 and MCT4 expressions decreased in the ipsilateral and
contralateral striatum and cortex
• Neuronal MCT2 expression was reduced but MCT4 expression appeared while
microvessels exhibited MCT2 expression at 24 hours
